Notice of Closed Meeting, 75019-75020 [2020-25960]
Download as PDF
<![CDATA[
Federal Register / Vol. 85, No. 227 / Tuesday, November 24, 2020 / Notices
J (see ‘‘General Routine Uses of Board
Systems of Records available at https://
www.federalreserve.gov/files/SORNpage-general-routine-uses-of-boardsystems-of-records.pdf). The BGFRS–24
SORN provides that the information
may be disclosed outside the Board in
accordance with general routine uses A,
B, C, D, E, F, G, I, and J (see id.). The
BGFRS–1 SORN also provides that all or
part of the record may be disclosed
outside of the Board in order to disclose
information to any source from which
additional information is requested (to
the extent necessary to identify the
individual, inform the source of the
purpose(s) of the request, and identify
the type of information requested),
when necessary to obtain information
relevant to a Board decision to hire or
retain an employee, issue a security
clearance, conduct a security or
suitability investigation of an
individual, classify jobs, let a contract,
or issue a license, grant or other benefit.
Correction
In the Federal Register of September
30, 2020, in FR Doc 2020–21604, on
page 61752, in the first column, correct
the ‘‘Date’’ and ‘‘Time’’ captions to read:
Date: January 12, 2021.
Time: 10:00 a.m.–6:00 p.m., EST.
The Director, Strategic Business
Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease
Control and Prevention, has been
delegated the authority to sign Federal
Register notices pertaining to
announcements of meetings and other
committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
[FR Doc. 2020–25959 Filed 11–23–20; 8:45 am]
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
BILLING CODE 4163–18–P
[FR Doc. 2020–25885 Filed 11–23–20; 8:45 am]
Centers for Disease Control and
Prevention
Notice of Closed Meeting
Centers for Disease Control and
Prevention
Disease, Disability, and Injury
Prevention and Control Special
Emphasis Panel (SEP)—DD21–001,
Study To Explore Early Development
(SEED) Follow Up Studies; Correction
Centers for Disease Control and
Prevention (CDC), Health and Human
Services.
ACTION: Notice; correction.
AGENCY:
The CDC published a
document in the Federal Register of
September 30, 2020, concerning a
closed meeting of the Disease,
Disability, and Injury Prevention and
Control Special Emphasis Panel (SEP)—
DD21–001, Study to Explore Early
Development (SEED) Follow up Studies.
The document contained incorrect
dates.
jbell on DSKJLSW7X2PROD with NOTICES
SUMMARY:
Jaya
Raman Ph.D., Scientific Review Officer,
CDC, 4770 Buford Highway, Mailstop
S107–8, Atlanta, Georgia 30341,
Telephone: (770) 488–6511, JRaman@
cdc.gov.
FOR FURTHER INFORMATION CONTACT:
SUPPLEMENTARY INFORMATION:
VerDate Sep<11>2014
17:48 Nov 23, 2020
Jkt 253001
Kalwant Smagh,
Director, Strategic Business Initiatives Unit,
Office of the Chief Operating Officer, Centers
for Disease Control and Prevention.
[FR Doc. 2020–25961 Filed 11–23–20; 8:45 am]
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Willowdale Road, Morgantown, WV
26506, Telephone: (304) 285–5951,
MGoldcamp@cdc.gov.
The Director, Strategic Business
Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease
Control and Prevention, has been
delegated the authority to sign Federal
Register notices pertaining to
announcements of meetings and other
committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Kalwant Smagh,
Director, Strategic Business Initiatives Unit,
Office of the Chief Operating Officer, Centers
for Disease Control and Prevention.
Board of Governors of the Federal Reserve
System, November 18, 2020.
Michele Taylor Fennell,
Deputy Associate Secretary of the Board.
BILLING CODE 6210–01–P
75019
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended, and the Determination of
the Director, Strategic Business
Initiatives Unit, Office of the Chief
Operating Officer, CDC, pursuant to
Public Law 92–463. The grant
applications and the discussions could
disclose confidential trade secrets or
commercial property such as patentable
material, and personal information
concerning individuals associated with
the grant applications, the disclosure of
which would constitute a clearly
unwarranted invasion of personal
privacy.
Name of Committee: Disease, Disability,
and Injury Prevention and Control Special
Emphasis Panel (SEP)–PAR 18–812, NIOSH
Member Conflict Review.
Date: February 22, 2021.
Time: 1:00 p.m.–5:00 p.m., EST.
Place: Teleconference.
Agenda: To review and evaluate grant
applications.
FOR FURTHER INFORMATION CONTACT:
Michael Goldcamp, Ph.D., Scientific
Reviewer Officer, Office of Extramural
Programs, CDC/NIOSH, 1095
PO 00000
Frm 00048
Fmt 4703
Sfmt 4703
BILLING CODE 4163–18–P
Centers for Disease Control and
Prevention
Notice of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended, and the Determination of
the Director, Strategic Business
Initiatives Unit, Office of the Chief
Operating Officer, CDC, pursuant to
Public Law 92–463. The grant
applications and the discussions could
disclose confidential trade secrets or
commercial property such as patentable
material, and personal information
concerning individuals associated with
the grant applications, the disclosure of
which would constitute a clearly
unwarranted invasion of personal
privacy.
Name of Committee: Disease,
Disability, and Injury Prevention and
Control Special Emphasis Panel (SEP)–
DD21–002, Characterizing the Natural
History of Fragile X Syndrome to Inform
the Development of Intervention
Outcome Measures.
Date: March 23, 2021.
Time: 10:00 a.m.–6:00 p.m., EST.
Place: Teleconference.
Agenda: To review and evaluate grant
applications.
FOR FURTHER INFORMATION CONTACT: Jaya
Raman Ph.D., Scientific Review Officer,
CDC, 4770 Buford Highway, Mailstop
S107–8, Atlanta, Georgia 30341,
E:\FR\FM\24NON1.SGM
24NON1
75020
Federal Register / Vol. 85, No. 227 / Tuesday, November 24, 2020 / Notices
Telephone: (770) 488–6511, JRaman@
cdc.gov.
The Director, Strategic Business
Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease
Control and Prevention, has been
delegated the authority to sign Federal
Register notices pertaining to
announcements of meetings and other
committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Kalwant Smagh,
Director, Strategic Business Initiatives Unit,
Office of the Chief Operating Officer, Centers
for Disease Control and Prevention.
[FR Doc. 2020–25960 Filed 11–23–20; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Administration for Children and
Families
Proposed Information Collection
Activity; Generic Clearance for the
Collection of Qualitative Feedback on
Agency Service Delivery (OMB #0970–
0401)
Administration for Children
and Families, HHS.
ACTION: Request for Public Comment.
AGENCY:
The Administration for
Children and Families (ACF) proposes
to extend data collection under the
existing overarching Generic Clearance
for the Collection of Qualitative
Feedback on Agency Service Delivery
(OMB #0970–0401). There are no
changes to the proposed types of
SUMMARY:
information collection or uses of data,
but ACF is requesting an increase to the
estimated number of respondents.
DATES: Comments due within 60 days of
publication. In compliance with the
requirements of Section 3506(c)(2)(A) of
the Paperwork Reduction Act of 1995,
ACF is soliciting public comment on the
specific aspects of the information
collection described above.
ADDRESSES: Copies of the proposed
collection of information can be
obtained and comments may be
forwarded by emailing infocollection@
acf.hhs.gov. Alternatively, copies can
also be obtained by writing to the
Administration for Children and
Families, Office of Planning, Research,
and Evaluation (OPRE), 330 C Street
SW, Washington, DC 20201, Attn: ACF
Reports Clearance Officer. All requests,
emailed or written, should be identified
by the title of the information collection.
SUPPLEMENTARY INFORMATION:
Description: Executive Order 12862
directs federal agencies to provide
service to the public that matches or
exceeds the best service available in the
private sector. As outlined in
Memorandum M–11–26, the Office of
Management and Budget (OMB) worked
with agencies to create a Fast Track
Process to allow agencies to obtain
timely feedback on service delivery
while ensuring that the information
collected is useful and minimally
burdensome for the public, as required
by the Paperwork Reduction Act of
1995. ACF created this generic clearance
in response to this effort by OMB.
In order to work continuously to
ensure that the ACF programs are
effective and meet our customers’ needs,
we use this Fast Track generic clearance
Instrument
jbell on DSKJLSW7X2PROD with NOTICES
Example instruments include:
Customer Comment Card/Complaint Form ............................................
Customer Satisfaction Survey
Usability Testing (e.g., Website or Software)
Small Discussion Group
Focus Group
Estimated Total Annual Burden
Hours: 12,500.
Comments: The Department
specifically requests comments on (a)
whether the proposed collection of
information is necessary for the proper
performance of the functions of the
agency, including whether the
information shall have practical utility;
(b) the accuracy of the agency’s estimate
of the burden of the proposed collection
of information; (c) the quality, utility,
VerDate Sep<11>2014
17:48 Nov 23, 2020
Jkt 253001
Frm 00049
Fmt 4703
Annual Burden Estimates
Based on the use of this generic
clearance over the past 3 years, ACF is
requesting an increase to the estimated
number of respondents from 10,000 to
12,500.
Total number
of respondents
Total number
of responses
per respondent
Average
burden hours
per response
Total burden
hours
12,500
1
.5
6,250
and clarity of the information to be
collected; and (d) ways to minimize the
burden of the collection of information
on respondents, including through the
use of automated collection techniques
or other forms of information
technology. Consideration will be given
to comments and suggestions submitted
within 60 days of this publication.
PO 00000
process to collect qualitative feedback
on our service delivery. This collection
of information is necessary to enable
ACF to garner customer and stakeholder
feedback in an efficient, timely manner
in accord with our commitment to
improving service delivery. The
information collected from our
customers and stakeholders helps
ensure that users have an effective,
efficient, and satisfying experience with
the programs. This feedback provides
insights into customer or stakeholder
perceptions, experiences, and
expectations; provides an early warning
of issues with service; or focus attention
on areas where communication,
training, or changes in operations might
improve delivery of products or
services. These collections allow for
ongoing, collaborative, and actionable
communications between ACF and its
customers and stakeholders. They also
allow feedback to contribute directly to
the improvement of program
management.
Per Memorandum M–11–26,
information collection requests
submitted under this Fast Track generic
will be considered approved unless
OMB notifies ACF otherwise within 5
days.
Respondents: ACF program
participants, potential program
participants, stakeholders, and other
customers.
Sfmt 9990
Authority: Social Security Act, Sec. 1110.
[42 U.S.C. 1310].
Mary B. Jones,
ACF/OPRE Certifying Officer.
[FR Doc. 2020–25978 Filed 11–23–20; 8:45 am]
BILLING CODE 4184–79–P
E:\FR\FM\24NON1.SGM
24NON1
]]>Agencies
[Federal Register Volume 85, Number 227 (Tuesday, November 24, 2020)]
[Notices]
[Pages 75019-75020]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-25960]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Notice of Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended, and the Determination of the Director, Strategic
Business Initiatives Unit, Office of the Chief Operating Officer, CDC,
pursuant to Public Law 92-463. The grant applications and the
discussions could disclose confidential trade secrets or commercial
property such as patentable material, and personal information
concerning individuals associated with the grant applications, the
disclosure of which would constitute a clearly unwarranted invasion of
personal privacy.
Name of Committee: Disease, Disability, and Injury Prevention and
Control Special Emphasis Panel (SEP)-DD21-002, Characterizing the
Natural History of Fragile X Syndrome to Inform the Development of
Intervention Outcome Measures.
Date: March 23, 2021.
Time: 10:00 a.m.-6:00 p.m., EST.
Place: Teleconference.
Agenda: To review and evaluate grant applications.
FOR FURTHER INFORMATION CONTACT: Jaya Raman Ph.D., Scientific Review
Officer, CDC, 4770 Buford Highway, Mailstop S107-8, Atlanta, Georgia
30341,
[[Page 75020]]
Telephone: (770) 488-6511, [email protected].
The Director, Strategic Business Initiatives Unit, Office of the
Chief Operating Officer, Centers for Disease Control and Prevention,
has been delegated the authority to sign Federal Register notices
pertaining to announcements of meetings and other committee management
activities, for both the Centers for Disease Control and Prevention and
the Agency for Toxic Substances and Disease Registry.
Kalwant Smagh,
Director, Strategic Business Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease Control and Prevention.
[FR Doc. 2020-25960 Filed 11-23-20; 8:45 am]
BILLING CODE 4163-18-P
